Zealand Pharma A/S (ZEAL)
After hours:
- GlobeNewswire
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
Company announcement – No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI) Dasiglucagon met the primary endpoint with statistical significance - reducing the requirement for intravenous glucose by 55% compared to placebo in this pediatric patient population (ages 7 days to 12 months) when compared to placebo. Dasiglucagon treatment was assessed as well-tolerated in this study and 11 out of 12 patie
- GlobeNewswire
Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device
Company announcement – No. 21 / 2022 Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device Deal includes $10 million USD upfront payment to Zealand and sales-based milestonesCertain inventory related to V-Go® and employees also included under the terms of the dealAgreement is part of Zealand’s refocused strategy to seek partners for commercial and late-stage assets while prioritizing research and development Copenhagen, May 17, 2022 – Zeala
- GlobeNewswire
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]
Company announcement – No. 20/ 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED] Copenhagen, DK and Boston, MA, May 12, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons dischargi
